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Background: In order to improve lung cancer survival in the UK, a greater proportion of resectable cancers must
be diagnosed. It is likely that resectability rates would be increased by more timely diagnosis. Aside from screening,
the only way of achieving this is to reduce the time to diagnosis in symptomatic cancers. Currently, lung cancers
are mainly diagnosed by general practitioners (GPs) using the National Institute for Health and Clinical Excellence
(NICE) guidelines for urgent referral for chest X-ray, which recommend urgent imaging or referral for patients who
have one of a number of chest symptoms for more than 3 weeks. We are proposing to expand this recommenda-
tion to include one of a number of chest symptoms of any duration in higher-risk patients.
Methods/Design: We intend to conduct a trial of imaging in these higher-risk patients and compare it with NICE
guidelines to see if imaging improves stage at diagnosis and resection rates. This trial would have to be large (and
consequently resource-intensive) because most of these patients will not have lung cancer, making optimal design
crucial. We are therefore conducting a pilot trial that will ascertain the feasibility of running a full trial and provide
key information that will be required in order to design the full trial.
Discussion: This trial will assess the feasibility and inform the design of a large, UK-wide, clinical trial of a change to
the NICE guidelines for urgent referral for chest X-ray for suspected lung cancer. It utilizes a combination of work-
shop, health economic, quality of life, qualitative, and quantitative methods in order to fully assess feasibility.
Trial registration: Clinicaltrials.gov NCT01344005Background
In 2010, lung cancer caused over 34,800 deaths in the
UK, accounting for 7% of all deaths and 22% of all
deaths from cancer [1,2]. Five-year survival in the UK is
just over 5%, compared with 13% in the USA and similar
proportions for several other EU countries [3]. Com-
pared with other countries, patients in the UK have
more advanced stage at presentation and a lower rate
of lung cancer resections (10%) [3-7]. It has been* Correspondence: hurtcn@cardiff.ac.uk
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UK because of probable later diagnosis of cancer [8-10].
Most commonly, lung cancer is diagnosed in the UK
following symptomatic presentation to primary care
[11]. NICE guidelines have identified the symptoms that
should trigger referral for a chest X-ray [12], and suspi-
cious chest X-rays should then be urgently referred to
secondary care [11]. The guidelines are currently being
updated.
Many patients have had symptoms for a year or more
prior to diagnosis [13,14]. Most of the overall time to
diagnosis is accounted for by patient or primary care
delay, with referral and secondary care delays accountingd. This is an Open Access article distributed under the terms of the Creative
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management of symptoms by GPs, before ordering an
X-ray, may delay the diagnosis [16]. A previous study
identified a range of factors that delayed GP referral
of patients for a chest X-ray including: symptom expe-
rience, lack of knowledge, fear, cultural factors, non-
standard patterns of healthcare utilization, underlying
stoical attitudes, and blame and stigma because of smok-
ing [17]. In the UK, only 23% of diagnoses are made
through urgent referrals based on NICE guidelines [18],
and patients who are diagnosed following an urgent
referral have more advanced TNM (tumor, node, metas-
tasis) stage compared with patients diagnosed through
other routes [19], suggesting that the guidance currently
identifies those with more advanced disease. The effect
of a more or less timely diagnosis is unproven in lung
cancer, although there are good arguments to suggest
benefit [20].
Several studies of screening with plain X-ray and spu-
tum cytology were undertaken in the 1970s and 1980s.
Although none found a mortality benefit [21-23], they
all had methodological weaknesses, with the controls re-
ceiving some screening, and small sample sizes resulting
in inadequate power. However, further information on
the value of plain X-ray has recently been provided by
the large PLCO (Prostate, Lung, Colorectal and Ovarian
Cancer Screening) Trial [24], which assessed the effects
of annual screening with modern chest radiography for
4 years in 77,445 subjects compared with 77,456 con-
trols who received usual care. Although screening de-
tected more cancers and more early-stage cancers, there
was no evidence of genuine benefit, with no reduction in
mortality over 13 years, either in the screened group as
a whole, or in a high-risk subgroup (based on the
National Lung Screening Trial (NLST) trial inclusion
criteria, see below).
The advent of low-dose computed tomography (CT)
provided a new tool for screening. In 2011, the landmark
American NLST reported the effect of screening for
3 years of current or former smokers aged 55 to 74 with
a smoking history of at least 30 pack-years: there was a
20% reduction in mortality from lung cancer and a 6%
decrease in all-cause mortality [25]. However, there were
serious costs incurred. Suspicious nodules requiring fur-
ther evaluation were found in 20% of the participants,
more than 90% of whom did not have lung cancer.
Over-diagnosis, meaning the identification of indolent
cancers that would never have become clinically appar-
ent, was estimated to apply to about 25% of the cancers
found [26]. It has been estimated that to implement this
program nationwide using the NLST inclusion and ex-
clusion criteria would cost $2 billion per annum in CT
scan costs alone [27]. When added to the complexities
of recruitment of a population that is likely to be hard toreach, and a complex interaction with smoking cessation
[28], it is unsurprising that widespread uptake of screen-
ing based on this protocol has not occurred.
The largest European low-dose CT screening study, the
Nederlands-Leuvens Longkanker Screenings Onderzoek
(NELSON) trial, used a longer screening interval than the
NSLT and a volumetric method of assessing nodules.
Although it has reported a favorable cancer-stage distri-
bution at diagnosis [29], determination of a genuine
stage shift at detection, from advanced stage to early
stage, will require comparison with the control group.
This has not yet been reported, and the size of any
benefit resulting from this method remains to be
determined.
On the current evidence, we believe that the current
best hope for improving outcomes in lung cancer re-
mains with earlier recognition of symptomatic disease at
presentation to primary care, and this is most readily
done with a chest X-ray. This is because patients who
are both high risk and symptomatic have a higher risk of
lung cancer than those high-risk patients included in the
aforementioned screening studies. A systematic review
of interventions to reduce patient and practitioner delay
in cancers did not identify any studies relating to lung
cancer [30]. A systematic review of interventions to re-
duce primary care delay in cancer referral did not find
any studies that reported a direct effect on reducing
delay, or any studies in lung cancer [30].
The intervention
We propose to lower the threshold (see Figure 1) for a
chest X-ray for potential lung cancer symptoms in high-
risk patients (that is, the new diagnostic strategy, termed
‘extra-NICE’). This will be compared with current NICE
guidance (‘NICE’). Extra-NICE recommends a chest X-
ray if one has not been obtained within the previous
3 months, the patient is aged over 60 years, and is a
smoker or ex-smoker with 10 or more pack-years of
smoking and with: a new or altered cough of any dur-
ation reported to primary care, and/or increased breath-
lessness or wheezing (whether or not associated with
purulent sputum).
Although tumor doubling time is variable, we
hypothesize that if tumors are identified earlier, it may
be possible to achieve a stage shift, which may translate
into higher rates of resections and other radical treat-
ments and an overall improvement in lung cancer
survival.
Main research question
Ultimately, we want to conduct a randomized trial to de-
termine whether or not our extra-NICE guidelines im-
prove lung cancer survival, using resection rates and
survival as outcome measures. Using resection rate,
NICE
Extra NICE
Presenting, but not meeting any threshold
haemoptysis, or any of the following unexplained or 
persistent (that is, lasting more than 3 weeks) symptoms 
or signs: cough, chest/shoulder pain, dyspnoea, weight 
loss, chest signs, hoarseness, finger clubbing, features 
suggestive of metastasis from a lung cancer (for 
example, in brain, bone, liver or skin), 
cervical/supraclavicular lymphadenopathy.
Figure 1 Thresholds for referral for chest X-ray.
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point of a full trial, and looking for an improvement
from 10% to 15%, we would require approximately 1,900
lung cancers, necessitating a UK-wide, expensive trial.
Using survival as the main endpoint would require even
more cancers. This pilot trial will provide information
that will inform the planning of the full trial.
This study fulfills the NETSCC (National Institute for
Health Research Trials and Studies Coordinating Centre)
definition of both a feasibility and pilot study because it
assesses how well the components of the full trial will
work together, key parameters that will be required to
plan the full trial, and whether or not it is realistically
achievable [31].
Clinical information
The basic clinical information required is as follows: the
prevalence of ‘extra-NICE’ symptoms in patients con-
sulting in UK general practice, the proportion of those
who agree to participate, and the proportion of those
who are diagnosed with lung cancer.
Of those patients diagnosed with lung cancer, we then
require: stage at diagnosis, performance status, and the
proportion of patients receiving radical treatments.
Process information
The process information required is: the feasibility of
primary care recruitment and randomization of pa-
tients to a chest X-ray, or not; the best sources of rou-
tine data for capturing lung cancers; the best way to
train GPs to identify and recruit eligible patients into
the trial; the most effective method of presenting the
trial (and randomization) to patients; barriers to re-
cruitment and how can we overcome them; and the
best measures of resource use and health-related
quality of life measures to facilitate health economicanalysis of the cost-effectiveness of the extra-NICE
protocol.
Methods/design
Study design
Ethics approval for the design described here was re-
ceived from the North Wales Research Ethics Commit-
tee (Reference: 11/WA/0222) and is in compliance with
the Helsinki Declaration.
The study will have two elements: a Working Group
and a pilot trial (see Figure 2) with qualitative and health
economic components.
The Working Group of patients and GPs will be con-
vened to establish: the best way to train clinicians to
identify and recruit eligible patients into the trial; and
the most effective method of presenting the trial (and
randomization) to patients (including review of Patient
Information Sheet and Informed Consent form).
The chief investigator (CI) will facilitate the Working
Group, which will consist of two patient representa-
tives, two non-academic GPs, two nurse practitioners,
research network representatives, the trial manager,
and a qualitative researcher. Proceedings will be
collated in a report highlighting key points to take
forward.
We will survey all GPs in South-East Wales to assess
the level of interest in the proposed full trial. For the
pilot trial, we will select approximately 20 general prac-
tices in south-east Wales, and a small number from
north Wales and south Yorkshire. GPs at these practices
will be trained to recruit patients who fulfill the require-
ments for extra-NICE (but who do not meet the NICE
threshold for referral). Patients willing to participate will
be individually randomized 1:1 to one of two arms. Arm
A will be the NICE guidance arm; the patient should
be treated according to current NICE guidance. Arm B
Conduct working groups with GPs and patients as to how to present trial and 
randomisation to patients
Recruit and train GPs 
Patients assessed for eligibility by GPs. Eligible patients are current or ex-smokers (any 
duration), aged 60+ with 10 or more pack-years of smoking and with at least one of the 
following:
a new or altered cough of any duration reported to primary care
increased breathlessness or wheezing (whether or not associated with purulent sputum). 
Allocated to urgent chest radiograph 
(n= 193)
Allocated to NICE guidance (n=193)
)
Individual 
randomisation (n=386)
2 months: Follow up with questionnaires by post 
12 months: Follow up in routine data sets 
Figure 2 Trial schema.
Hurt et al. Trials 2013, 14:405 Page 4 of 9
http://www.trialsjournal.com/content/14/1/405will use the extra-NICE protocol; that is, urgent refer-
ral for chest X-ray: the GP orders an urgent chest
X-ray through the usual local process.
Participant eligibility
Eligible patients will be identified within general prac-
tices, either during consultations, in chronic obstructive
pulmonary disease (COPD) clinics or by retrospective
searches of the records of the previous week’s consulta-
tions. To be eligible to be included in the trial the pa-
tient must meet all of the following criteria: 1) age over
60 years, 2) smoker or ex-smoker (any duration) with 10
or more pack-years of smoking (assessed using http://
smokingpackyears.com/. or by dividing the number of
cigarettes smoked per day by 20 and multiplying by the
number of years smoked), and 3) has given written in-
formed consent; and at least one of the following cri-
teria: 1) a new or altered cough of any duration reported
to primary care or 2) increased breathlessness or wheez-
ing (whether or not associated with purulent sputum).
None of the following categories of patients can be
included in the trial: 1) patients who qualify for urgent
referral for chest X-ray under NICE guidelines that is,
hemoptysis, or any of the following unexplained or per-
sistent (that is, lasting more than 3 weeks) symptoms or
signs: cough, chest/shoulder pain, dyspnea, weight loss,
chest signs, hoarseness, finger clubbing, features suggest-
ive of metastasis from a lung cancer (for example, in
brain, bone, liver or skin), or cervical/supraclavicular
lymphadenopathy; 2) patients who have had a chest X-
ray or CT scan of the chest in the previous 3 months; 3)patients who need a chest X-ray within the following
3 weeks for reasons other than those listed above; or 4)
patients previously diagnosed with cancer who have a
life expectancy of less than 1 year.
Sample size considerations
Estimating the prevalence of extra-NICE symptoms in
patients consulting UK general practices
We have modeled the study using the CAPER (Cancer
Prediction in Exeter) lung database [12,15], which con-
tains all primary care consultations, symptoms, and in-
vestigations in the 2 years before diagnosis for a 5-year
cohort of 247 lung cancer cases, to estimate the poten-
tial benefit of expanded chest X-ray use. Smokers aged
over 60 years make up 3.2% of the UK population, and
we estimate that in a 1-year period, 24% of these would
present with extra-NICE symptoms only; that is, 0.768%
(or 42 per year in an average practice of 5,500 patients).
Hence, if we were to recruit 26 practices (each with a
patient population of 5,500) and recruited patients over
an average of 6 months (a 12 month recruitment period
with practices opening at different points throughout
that period), we could get an estimate of this with confi-
dence intervals of 0.70 to 0.83% from a patient-year
population of 71,500 (26 × 5,500 × 0.5).
Estimating the proportion of those with extra-NICE symp-
toms who will agree to participate
If we were to find a prevalence of extra-NICE symptoms
of 0.768% per year then, from the above, we might find
550 patients eligible for the study. Studies conducted at
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rate of eligible patients into trials. We could get an
estimate of this with confidence intervals of 70 to 74% in
this study.
Estimating the proportion of those who agree to participate
and who are diagnosed with lung cancer
If 386 (70%) eligible patients consented to participate in
the trial, then we could get 95% confidence intervals of
0.9 to 3.9% around an estimate of 2.4% (from CAPER
lung database) of those who will be diagnosed with lung
cancer.
It was decided to try to open all practices to recruit-
ment for at least 12 months during the running of the
trial, so as to avoid any selection bias caused by symp-
tom seasonality.
Method of randomization
Randomization will take place centrally at the Bristol
Randomised Trials Collaboration using either an auto-
mated telephone or a secure online service. Partici-
pants will be randomized using minimization with a
random element. This will ensure balanced treatment
allocation by a number of clinically important factors:
GP practice, age (<75 or ≥75 years), and COPD diagno-
sis. Randomization will have an allocation ratio of 1:1.
Outcome measures and statistical analysis
The primary analysis will be intention to treat.
Primary outcome measures
The primary outcome measures are as follows.
 The prevalence of extra-NICE symptoms in patients
consulting a UK general practice. Participating prac-
tices will be asked to log a count of all eligible pa-
tients. The prevalence will be calculated as the total
number of eligible patients logged by the participat-
ing practices divided by the total number of patients
on their lists.
 The proportion of those who agree to participate.
This will be known from trial recruitment, and
calculated as the total number of patients recruited
by the participating practices divided by the total
number of eligible patients logged by them.
 The proportion of those that are diagnosed with
lung cancer. This will be obtained from the UK
National Lung Cancer Audit Database (LUCADA;
available from the NHS Information Centre) and the
general practices. It will be calculated as the total
number of participating patients found to have lung
cancer divided by the total number of patients
recruited. A statistical comparison of the proportion
in each arm will be made.Secondary outcome measures
We will also assess the following secondary outcome
measures
 Of those patients diagnosed with lung cancer, we
will assess stage at diagnosis, performance status,
and the proportion of patients receiving radical
treatments. This will be obtained from LUCADA
and the general practices, and proportions will be
presented overall and by trial arm.
 Anxiety/depression that may be caused by
unnecessary or no chest X-rays. This will be mea-
sured using the Hospital Anxiety and Depression
Scale (HADS) [32] and informed by the qualitative
interviews. This will be presented overall and by
trial arm.
 Assessment of false-positive (suspicion of cancer on
X-ray but no subsequent cancer diagnosis within
6 months) and false-negative (no suspicion of cancer
on the X-ray but diagnosis of lung cancer within
6 months) rates for the chest X-rays. This will be
obtained from LUCADA and the general practices,
and proportions will be presented overall and by
trial arm.
 Cost-effectiveness of extra-NICE. This will be mea-
sured by a Client Service Receipt Inventory (CSRI),
the ICECAP (O) (Investigating Choice Experiments
for the Preferences of Older People (ICEPOP) Cap-
ability measure [33], and the EQ-5D-3 L (EuroQol 5
Dimensional Health State Questionnaire). The CSRI
completed by the patient will be compared against
data about resource use available from the GP to
ascertain the best method of capturing these data
in the full trial.
The following processes will be reviewed and refined
during the workshop at the start of the trial, during
qualitative interviews, and continuously throughout the
trial by the trial management group (TMG): 1) the best
way to train GPs to identify and recruit eligible patients
into the trial; 2) the most effective method of presenting
the trial (and randomization) to patients and 3) barriers
to recruitment and how can we overcome them,
Data collection
Screening
The number of eligible patients and the number of those
who consented will be recorded by each general practice
on screening logs.
Baseline data
Patient name, NHS number, Trial number, and their ad-
dress will be collected to facilitate data linkage with rou-
tine datasets and administration of postal questionnaires
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sent by fax at the general practice to a secure fax at the
Wales Cancer Trials Unit (WCTU) by the practice staff
as soon as possible after the patient is randomized. The
original consent form will then be stored in the Investi-
gator Site File at the practice.
The following data will be collected on a Case Report
Form (CRF) (using non-carbon copy paper) completed
by staff at the general practice at the time of recruit-
ment: trial number, patient initials, date of birth, gender,
ethnicity, socioeconomic status, and educational level;
co-morbidity (Charlson Index); venue for determination
of eligibility; primary reason for presenting; ex-smoker
or current smoker, number ofpack years, and the quit
date for ex-smokers; presence of pre-existing lung dis-
ease; date of previous chest X-ray in the preceding
12 months; and presenting symptoms and duration.
The ICECAP(O), HADS, EQ-5D-3 L and CSRI will
be given to the patient to complete at the time of
randomization.
Two months after randomization
The ICECAP (O), HADS, EQ-5D-3 L, and CSRI will be
posted to the patient at home to complete and return in
a stamped addressed envelope. Patients will also be in-
vited to give open comments about their experience on
the trial. Staff at WCTU will check first with the pa-
tient’s GP to ensure that they are still alive before send-
ing the questionnaires to the patient’s home address. If
the patient returns the completed questionnaires, then
they will be sent a £5.00 voucher as thanks. A reminder
letter will be sent if no response is received within
2 weeks, and a telephone call reminder will be made if
there is no response within 4 weeks [34]. A score on the
completed HADS questionnaires of either less than 16
for anxiety or less than 11 for depression will trigger let-
ters indicating the high scores to both the patient and
their GP.
During the trial
General practices will be asked to append an additional
sheet onto the chest X-ray request forms or letters for
the patients randomized to either arm of the trial. This
sheet will highlight that the patient is part of a trial, and
will ask the radiology department to fax a copy of the
chest X-ray result to the WCTU secure fax. In the case
of missing forms, the GP practice will be contacted and
asked to fax this to WCTU.
Twelve months after randomization
LUCADA will be used to collect the following data by
data linkage: date of diagnosis of lung cancer; lung can-
cer stage at diagnosis; date of resection; WHO perform-
ance status at diagnosis; and date and cause of death.Additionally, 12 months after randomization is com-
pleted, general practices will be sent a list of the patients
that they have enrolled into the trial and asked to return
the following information to WCTU: 1) a completed
CRF with the following data for those patients: health re-
source use because being enrolled into the trial; and
follow-up of any abnormal/indeterminate chest X-rays
(for example, any repeat X-rays performed, and results
of any biopsies); 2) a print-out (from the practice
computer system) of all consultations with GPs and
nurses, all prescriptions, and all results of GP-initiated
investigations.
Health economics
This feasibility study offers the opportunity to explore
the most research-efficient way of incorporating eco-
nomic evaluation into the full trial [35]. Specifically, we
will focus on piloting methods for collecting primary
and secondary care resource use using routine data as
compared with patient recall (which is unlikely to be sat-
isfactory given the complexity of cancer treatment). We
will also have the opportunity to pilot use of the EQ-5D-
3 L and ICECAP (O) in this population group and diag-
nostic context. Although the EQ-5D-3 L instrument is
the most widely used generic quality of life measure in
economic evaluation studies for quality-adjusted life
years calculation, it still requires methodological bench-
marking against other health-related quality of life mea-
sures. Specifically there is growing interest in the
ICECAP (O) measure, which is based on capability the-
ory rather than the more functional aspects of health-
related quality of life as in EQ-5D.
Qualitative interviews
The qualitative component will explore: 1) GPs’ experi-
ences of recruiting and consenting patients, including
the time and logistical implications of these experi-
ences; and 2) Patient response to recruitment and
participation.
It is anticipated that the data from this component of
the trial will be used to help identify: the best way to
train primary care staff to identify and recruit eligible
patients into the trial; the most effective method of pre-
senting the trial (and randomization) to patients; and
barriers to recruitment and potential solutions.
Sampling strategy
Qualitative interviews will be conducted with four
groups: a sample of GPs, patients randomized to extra-
NICE, patients randomized to NICE, and, if possible, pa-
tients who refuse participation in the trial. We expect
that interviews with 10 GPs and up to 30 patients from
across the three groups will be sufficient to gain the
required insight, and this is in line with the usual
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lysis [36]. Participants will be purposively selected until
the required number is recruited.Obtaining consent and approaching patients
Consent for the GP interviews will be sought at the time
they agree to participate in the trial. All patients who are
invited to participate in the trial will be asked at this
time to additionally consent to be interviewed, although
it will be explained that only a small number of patients
will be approached for interview. Patients who refuse
participation in the clinical trial will also be invited at
this time to consent to an interview about their reasons
for non-participation. A separate Participant Informa-
tion Sheet and Consent Form for the qualitative
interviews will be provided to trial participants. The
researcher will receive from the participating general
practices, the name, address, and telephone number of
all participants who have consented to be interviewed.
The research interviewers will contact participants
who consent and arrange a convenient time and loca-
tion for interview. as follows. Non-trial participants
will be contacted as soon as possible after consent is
obtained, patients in the trial arms will be contacted
once consent and randomization has taken place, and
GPs will be contacted once recruitment to the trial is
underway.
The GP interviews will be split into three groups; low,
medium, and high recruiters. Convenience sampling will
be used to recruit participants to the interviews, that is,
they will be contacted by the researcher following their
clinical appointment with the GP and having given
consent.The interviews
Individual participants will be interviewed at home or in
a quiet clinic location, according to their preference. The
interviews will be semi-structured according to an initial
interview schedule. The schedule will be adjusted to ac-
count for patient-led topics, if necessary, following the
first two or three interviews. This iterative process al-
lows the patients’ topic(s) of interest to be heard and
accounted for within the data collection. The interviewer
will digitally record the interview, but will also make
field notes (with the patient’s permission) to record inci-
dents occurring during the interview, non-verbal com-
munication, or reactions at the time of the interview.
Interviews will be 30 to 60 minutes in length, and will
be terminated earlier if the participant is thought to be
fatigued or becomes unwell. Ideally, patients will be
interviewed alone but, if they prefer, a friend or relative
may be present.Data transfer and transcription
The interviewer will upload the digital media files onto a
secure computer, and files will be labeled with a study
number. No identifiable data will be stored. Digital files
will be stored at the WCTU. The transcription secretary
at the WCTU will transcribe the interviews verbatim,
and following the WCTU transcription, will use stand-
ard operating procedures to ensure data protection and
confidentiality. The transcripts will be uploaded to the
NVivo 8 qualitative software program for efficient data
management.
Analytic framework
Data analysis will be performed using a Framework ap-
proach [36]. This is a pragmatic approach to qualitative
data analysis that emerged from policy research.
The quality and veracity of the analysis will be checked
throughout. For example, if during analysis, the re-
searcher is uncertain of the meaning or interpretation
of a section of interview data, the participant will be
contacted for verification. In addition, double coding
and analysis will be conducted by the qualitative lead.
Ongoing supervision and discussion with senior re-
searchers and the trial team will support the reflexivity
of the researcher and reflection on their interpretation
in order to ensure findings are grounded in the data.
Presentation of results
The anonymized data will be represented by selected
extracts in a narrative format with a thematic structure.
The results will be discussed with data extracts used
in support of claims made. The TMG will review the
results to assess potential alterations to trial design, and
will include the qualitative analysis to complement the
reporting of the full trial, where appropriate.
Discussion
This trial will assess the feasibility and inform the design
of a large, UK-wide, clinical trial of a change to the NICE
guidelines for urgent referral for chest X-ray for sus-
pected lung cancer. It utilizes a combination of work-
shop, health economics, quality of life, qualitative and
quantitative methods in order to fully assess feasibility.
This study has been designed as an individually ran-
domized study. The design team debated the merits of
cluster randomization (with practices being randomized
to either Arm A or Arm B) to ease the administrative
burden associated with recruiting patients and to pre-
vent potential contamination by patients randomized to
Arm A potentially seeking chest X-rays elsewhere.
However, cluster randomization may have created selection
bias with more patients potentially being recruited into
Arm A practices. Additionally, cluster randomization re-
quires more patients in power calculations for comparisons
Hurt et al. Trials 2013, 14:405 Page 8 of 9
http://www.trialsjournal.com/content/14/1/405of primary endpoints (to account for the clustering), which
would make a future definitive trial more difficult to
achieve.Trial status
At the time of manuscript submission, this trial was still
in the patient recruitment phase.
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